Short communication · 4 Aug 2026
Conference abstractPublished 22 Oct 2018
Use of sacubitril/valsartan in patients with cardiotoxicity due to chemotherapy and heart failure
Argentina Society of Cardiology, Argentina
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Background & Aim: Heart failure is a term used to define a constellation of symptoms and signs that are commonly attributed to the inability of the heart to produce a cardiac output that meets the demands of the body. It remains a deadly disease, affecting between 1-2% of the population and is more common in the elderly, with around 6-10% of patients over 65 suffering from the condition. Sacubitril/valsartan (LCZ-696) is a combined neprilysin inhibitor and angiotensin AT1 receptor blocker approved in recent years for the treatment of chronic heart failure with reduced ejection fraction. In an area where there have been limited pharmacological advances in the last 10 years, this drug was a game changer and a great one. The optimal use of sacubitril/valsartan in clinical practice needs further investigation, in particular for patients with cardiomyopathy induced by chemotherapeutic toxicity as such patients are usually poorly represented in clinical trials. Method: 490 consecutive patients (p) with a history of breast cancer, who received treatment with chemotherapy, were enrolled prospectively from June 2016 to June 2017. Ventricular dysfunction was detected through clinical, echocardiographic and laboratory tests. For the statistical analysis the SPSS was used. Result: 490 patients, aged 69±7.2 years, female 482 (98.3%). 14 p presented ventricular dysfunction refractory to conventional treatment, all were optimally treated with beta-blockers, being with an average heart rate of 61±9 bpm, so in this group it was decided to rotate the angiotensin II receptor blocker treatment to the sacubitril/valsartan combination, whose titration was adjusted to the clinical response and the hemodynamic parameters. They were followed up at 14, 28 days and at 3 and 6 months. It was observed that at 3 months the patients improved the ejection fraction of the left ventricle (average 23% to 36%). Improvement of ProBNP 934 pg/ml (basal), with an average reduction of 30% at follow-up, normalizing in 100% of patients followed up at 3 months. Improvement of CF III-IV to CF I-II is observed in 100% of patients. The dose of loop diuretics was reduced in all patients. Conclusion: In patients with ventricular dysfunction secondary to chemotherapy and refractory to the tried and tested therapy, sacubitril/valsartan has shown a good safety profile with excellent results in follow-up and it would be a promising alternative in this cohort of patients.
Subjects
CardiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Clinical and Experimental Cardiology.
Conference abstract · 15 Jun 2026
Speckle Tracking Echocardiography for Early Identification of Chemotherapy-Induced Cardiotoxicity
Conference abstract · 15 Jun 2026
Coronary CT Angiography as a First-Line Diagnostic Tool for Stable Chest Pain: Clinical Outcomes from a Multicenter Study
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalClinical and Experimental Cardiology
- SubjectCardiology
- BylineArticles whose byline prints “Vanesa Gregorietti”

